AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Future Prospects | Analyst targets range from $5 to $28 per share, reflecting optimism about AbCellera's internal pipeline development and manufacturing capabilities |
Strategic Alliances | Explore AbCellera's partnerships with industry giants like Biogen, potentially unlocking new therapeutic avenues and creating additional value streams |
Financial Fortitude | With nearly $1 billion in liquidity, AbCellera boasts a strong financial foundation, though analysts note potential challenges in near-term revenue generation |
Biotech Breakthrough | AbCellera's innovative antibody discovery platform, validated through COVID-19 efforts, positions the company at the forefront of drug development technology |
Metrics to compare | ABCL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipABCLPeersSector | |
---|---|---|---|---|
P/E Ratio | −4.7x | −5.0x | −0.5x | |
PEG Ratio | 0.56 | 0.17 | 0.00 | |
Price / Book | 0.7x | 2.5x | 2.6x | |
Price / LTM Sales | 26.6x | 4.6x | 2.9x | |
Upside (Analyst Target) | 250.2% | 40.4% | 54.5% | |
Fair Value Upside | Unlock | 9.8% | 8.5% | Unlock |